[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368877-105":59,"doc-detail-368877-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","screening-the-irish-marine-biorepository-identifies-a-new-bryostatin-analog-as-potent-inhibitor-of-activated-b-cells-diffuse-large-b-cell-lymphoma","Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma","","Aggressive activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) responds poorly to standard therapy, motivating discovery of new anticancer leads. A 435-fraction library from the Irish marine biorepository was screened on ABC-DLBCL cell lines (TMD8, OCI-Ly10) with CB33 as a non-cancer control. Active fractions prioritized potency and selectivity and revealed nanomolar cytotoxicity. Transcriptomic profiling highlighted pathway modulation by an 18-demethylated bryostatin analog, identifying Antiopella cristata and Diplosoma listerianum as enriched reservoirs of bioactive bryostatins.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/screening-the-irish-marine-biorepository-identifies-a-new-bryostatin-analog-as-potent-inhibitor-of-activated-b-cells-diffuse-large-b-cell-lymphoma/368877/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/screening-the-irish-marine-biorepository-identifies-a-new-bryostatin-analog-as-potent-inhibitor-of-activated-b-cells-diffuse-large-b-cell-lymphoma/368877.png","ImageObject",300,407,{"name":92,"@type":93},"Mary Man","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in ABC-DLBCL?","Question",{"text":112,"@type":113},"ABC-DLBCL is an aggressive lymphoma subtype with poor response to standard chemotherapy and inferior outcomes compared with other DLBCL variants, creating a need for new effective compounds.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were candidate compounds identified and prioritized?",{"text":117,"@type":113},"A library of 435 marine fractions from the Irish marine biorepository was screened against ABC-DLBCL cell lines and a non-cancer control, with active fractions prioritized based on potency and selectivity, followed by bioassay-guided fractionation.",{"name":119,"@type":110,"acceptedAnswer":120},"What key finding relates bryostatin analogs to the lymphoma model?",{"text":121,"@type":113},"A newly characterized bryostatin analog, including an 18-demethylated analog, showed nanomolar cytotoxicity against ABC-DLBCL cell lines, while transcriptomic profiling suggested modulation of key signaling pathways.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368877,1790273903,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","ChemBioChem  \nResearch Article  \n[doi.org/10.1002/cbic.202500500](doi.org/10.1002/cbic.202500500)  \n[www.chembiochem.org](www.chembiochem.org)  \nScreening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma  \nLaurence K. Jennings, Filippo Spriano, Maggie M. Reddy, Luciano Cascione, Elisa Civanelli, Andrea Rinaldi, Francesco Bertoni,* and Olivier P. Thomas*  \n\n| Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an | several bryostatin analogs, including bryostatin 13 and a new |\n| --- | --- |\n| aggressive cancer with poor response to standard chemotherapy. | natural product, its 18-demethylated analog. Both compounds |\n| In search of new therapeutic leads, a library of 435 fractions pre- | demonstrated nanomolar cytotoxicity against ABC-DLBCL cell |\n| pared from the Irish marine biorepository was screened against | lines with minimal activity in CB33. Transcriptomic profiling |\n| 2 ABC-DLBCL cell lines (TMD8 and OCI-Ly10) and a non-cancerous | showed significant gene expression changes, particularly for the |\n| control cell line (CB33) . Active fractions are prioritized based on | 18-demethylated analog, implicating modulation of key signaling |\n| potency and selectivity. Among them, fractions from the nudi- | pathways. This study identifies A. cristata as a novel and highly |\n| branch Antiopella cristata and the ascidian Diplosoma listerianum | enriched source of bioactive bryostatins and supports the dietary |\n| exhibit the most potent and selective cytotoxicity. Bioassay-guided | sequestration hypothesis in nudibranchs, highlighting the value of |\n| fractionation of D. listerianum led to the identification of the known | marine invertebrates as reservoirs of selective anticancer agents for |\n| loliolide and epiloliolide. On the other hand, A. cristata yielded | drug discovery. |\n| 1. Introduction\u003Cbr>Cancer constitutes a major cause of mortality worldwide, with lymphoma representing the most prevalent hematologic malignancy. The majority of lymphoma cases are diagnosed in individuals over 60 years of age, and epidemiological data indicate a rising incidence in recent years. [1] Diffuse large B-cell lymphoma (DLBCL)\u003Cbr>L. K. Jennings, M. M. Reddy, O. P. Thomas\u003Cbr>School of Biological and Chemical Sciences\u003Cbr>Ryan Institute\u003Cbr>University of Galway\u003Cbr>University Road, Galway H91 TK33, Ireland\u003Cbr>E-mail: olivier.thomas@universityofgalway.ie\u003Cbr>F. Spriano, L. Cascione, E. Civanelli, A. Rinaldi, F. Bertoni\u003Cbr>Institute of Oncology Research, Faculty of Biomedical Sciences\u003Cbr>USI\u003Cbr>via F. Chiesa 5, 6500 Bellinzona, Switzerland\u003Cbr>E-mail: [francesco.bertoni@ior.usi.ch](francesco.bertoni@ior.usi.ch)\u003Cbr>L. Cascione\u003Cbr>SIB Swiss Institute of Bioinformatics\u003Cbr>1000 Lausanne, Switzerland\u003Cbr>F. Bertoni\u003Cbr>Oncology Institute of Southern Switzerland\u003Cbr>Ente Ospedaliero Cantonale\u003Cbr>6500 Bellinzona, Switzerland\u003Cbr> Supporting information for this article is available on the WWW under [https://](https://)[ ](https://)[doi.org/10.1002/cbic.202500500](doi.org/10.1002/cbic.202500500)\u003Cbr> © 2025 The Author(s). ChemBioChem published by Wiley-VCH GmbH. This isan open access article under the terms of the Creative Commons AttributionNonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is noncommercial and no modifications or adaptations are made. | is the most prevalent type of lymphoma, constituting 􀀁 30% of all cases. [2] The standard frontline immune-chemotherapeutic treatment for DLBCL, known as R-CHOP, consists of a CD20-targeting monoclonal antibody (rituximab), three chemotherapy drugs (cyclophosphamide, doxorubicin, and vincristine), and a glucocorticoid (prednisone or prednisolone) .[3] While these treatments achieve favorable therapeutic rates (60–70%) for most variants of DLBCL, the activated B-cell-like (ABC) subtype, which accounts for roughly 35% of DLBCL, exh","cbCaioJHyWUfcNAz","https://ap.wps.com/l/cbCaioJHyWUfcNAz","pdf",987694,"English","# Introduction\n# Results and Discussion","[{\"question\":\"What problem does the study address in ABC-DLBCL?\",\"answer\":\"ABC-DLBCL is an aggressive lymphoma subtype with poor response to standard chemotherapy and inferior outcomes compared with other DLBCL variants, creating a need for new effective compounds.\"},{\"question\":\"How were candidate compounds identified and prioritized?\",\"answer\":\"A library of 435 marine fractions from the Irish marine biorepository was screened against ABC-DLBCL cell lines and a non-cancer control, with active fractions prioritized based on potency and selectivity, followed by bioassay-guided fractionation.\"},{\"question\":\"What key finding relates bryostatin analogs to the lymphoma model?\",\"answer\":\"A newly characterized bryostatin analog, including an 18-demethylated analog, showed nanomolar cytotoxicity against ABC-DLBCL cell lines, while transcriptomic profiling suggested modulation of key signaling pathways.\"}]","Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B-Cells Diffuse Large B-Cell Lymphoma | PDF",1790179042,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9114fdb48d05cd7d3f3b00af7acf65e.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3634953f966124b871c3a65bdcd80dc1.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a348190fed91c2f6f73df9b854b39478.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39efc4cdab1c8bced1c01b4ef95a766c.webp",980,1287]